Evaluation of the disease burden of hepatitis C in China, 1990-2019
Author:
Affiliation:

1.Department of Hepatology, Kunming Third People's Hospital/Yunnan Infectious Diseases Clinical Medical Center, Kunming 650041, China;2.Department of Hepatopancreatobiliary, The First People's Hospital of Yunnan Province, Kunming 650041, China;3.Department of Disease Control and Prevention, The First People's Hospital of Yunnan Province, Kunming 650034, China

Clc Number:

+3]]>

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Comments
    Abstract:

    Objective To analyze the changing trend of disease burden and epidemic situation of hepatitis C in China from 1990 to 2019, and provide scientific basis for promoting the elimination of hepatitis C. Methods Data of the Global Burden of Disease Study 2019 (GBD 2019) were used to analyze the 30-year changing trend and current situation of the occurrence, onset, disability-adjusted life year (DALY) and years of life lost (YLL) of hepatitis C in Chinese population, GraphPad Prism 8.0 was used for mapping. Results In 2019, standardized DALY rate of the total disease burden of hepatitis C in China was about 101/100 000 person-year; the standardized incidence of acute hepatitis C was about 47/100 000; the peak incidence of hepatitis C-related chronic liver disease was in population of 40-44 years old, and standardized morbidity was about 1 247/100 000. From 1990 to 2019, the total standardized incidence and standardized morbidity of hepatitis C dropped to the trough in 2015, and then rose sharply in the following 4 years; standardized DALY rate has been declining for 30 years. Conclusion Hepatitis C-related chronic liver disease is the main disease burden of hepatitis C; due to the short treatment cycle and good efficacy of direct antiviral drugs, it is recommended to strengthen publicity, strengthen hepatitis C screening, and promote the construction of a healthy China.

    Reference
    Related
Get Citation

李生浩,张黎,张瑞仙.1990—2019年中国丙型病毒性肝炎疾病负担评估[J].中国感染控制杂志英文版,2022,(10):971-976. DOI:10.12138/j. issn.1671-9638.20222754.
Sheng-hao LI, Li ZHANG, Rui-xian ZHANG. Evaluation of the disease burden of hepatitis C in China, 1990-2019[J]. Chin J Infect Control, 2022,(10):971-976. DOI:10.12138/j. issn.1671-9638.20222754.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:April 12,2022
  • Revised:
  • Adopted:
  • Online: April 28,2024
  • Published: